Veru Inc (VERU)

Apr 04, 2026

Veru signals Q3 2025 regulatory clarity for enobosarm Phase 3 trial - MSN

Apr 04, 2026

Apr 02, 2026

MACD Signal: Is Veru Inc benefiting from innovation trendsWeekly Profit Summary & Free Community Consensus Stock Picks - baoquankhu1.vn

Apr 02, 2026

Apr 02, 2026

Veru SEC Filings - Stock Titan

Apr 02, 2026

Mar 30, 2026

Veru Q1 2026 earnings preview - MSN

Mar 30, 2026

Mar 30, 2026

Veru Inc. (VERU) Stock Price Quote Today & Current Price Chart - Capital.com

Mar 30, 2026

Mar 27, 2026

Veru (NASDAQ:VERU) Shares Cross Below 200 Day Moving Average – Here’s Why - Defense World

Mar 27, 2026

Mar 26, 2026

FRA:FMW0 PB Ratio: 1.74 — 41% Below Median - GuruFocus

Mar 26, 2026

Mar 25, 2026

Veru outlines Phase III plans for enobosarm and signals upcoming FDA clarity on lean mass preservation in obesity treatment - MSN

Mar 25, 2026

Mar 22, 2026

If You Invested $1,000 in Veru (VERU) - Stock Titan

Mar 22, 2026

Mar 21, 2026

Volume Recap: Is Veru Inc attractive for institutional investors2026 Volume & Weekly High Return Stock Forecasts - baoquankhu1.vn

Mar 21, 2026

Mar 14, 2026

Veru Inc. Amends 2018 Equity Incentive Plan and Reports Annual Meeting Results – Form 8-K Filing March 12, 2026 - Minichart

Mar 14, 2026

Mar 13, 2026

Veru Shareholders Expand Equity Plan, Reelect Board Leadership - TipRanks

Mar 13, 2026

Mar 13, 2026

Veru (NASDAQ: VERU) investors back larger equity plan, board slate and auditor - Stock Titan

Mar 13, 2026

Mar 13, 2026

Aug Macro: Is Veru Inc attractive for institutional investors2026 Opening Moves & Daily Market Momentum Tracking - baoquankhu1.vn

Mar 13, 2026

Mar 11, 2026

Veru Inc. (NASDAQ: VERU) Q1 2026 earnings call transcript - MSN

Mar 11, 2026

Mar 10, 2026

Veru Targets GLP-1 Muscle Loss Risk With New Enobosarm Combo Study - TipRanks

Mar 10, 2026

Mar 09, 2026

Veru enrolls first patient in obesity drug combination trial By Investing.com - Investing.com Canada

Mar 09, 2026

Mar 09, 2026

Veru (VERU) Launches Phase 2b Trial for Obesity Treatment - GuruFocus

Mar 09, 2026

Mar 09, 2026

Veru enrolls first patient in Phase 2b PLATEAU trial of enobosarm - TipRanks

Mar 09, 2026

Mar 09, 2026

Veru enrolls first patient in obesity drug combination trial - Investing.com Australia

Mar 09, 2026

Mar 09, 2026

Veru Inc. Initiates Phase 2b Clinical Trial for Enobosarm to Enhance Weight Loss in Older Patients with Obesity Receiving Semaglutide - Quiver Quantitative

Mar 09, 2026

Mar 09, 2026

Veru Enrolls First Patient in Phase 2b PLATEAU Clinical Trial of Enobosarm and Semaglutide Combination for High Quality Weight Loss - Yahoo Finance

Mar 09, 2026

Mar 06, 2026

VERU Earnings History & Surprises | EPS & Revenue Results | VERU INC (NASDAQ:VERU) - ChartMill

Mar 06, 2026

Mar 03, 2026

Veru Inc. (VERU) Presents at Oppenheimer 36th Annual Healthcare Life Sciences ConferenceSlideshow - Seeking Alpha

Mar 03, 2026

Mar 02, 2026

Veru : Corporate Presentation, February 2026 - marketscreener.com

Mar 02, 2026

Feb 28, 2026

VERU Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI

Feb 28, 2026

Feb 27, 2026

VERU Should I Buy - Intellectia AI

Feb 27, 2026

Feb 26, 2026

Veru at Oppenheimer Conference: Strategic Insights into Obesity Drug Development - Investing.com

Feb 26, 2026

Feb 26, 2026

VERU PE Ratio & Valuation, Is VERU Overvalued - Intellectia AI

Feb 26, 2026

Feb 19, 2026

Aug Volume: Is CHGG vulnerable to short sellersJuly 2025 Volume & Expert Curated Trade Setup Alerts - baoquankhu1.vn

Feb 19, 2026

Feb 19, 2026

Veru to Present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference - Bitget

Feb 19, 2026

Feb 16, 2026

Tootsie Roll among names set to join Russell 3000 Index, Growgeneration, Veru set to leave - Intellectia AI

Feb 16, 2026

Feb 15, 2026

Will Veru Inc. benefit from sector rotationWeekly Trend Summary & Long-Term Capital Growth Strategies - mfd.ru

Feb 15, 2026

Feb 14, 2026

Aug Closing: Can PIII outperform under higher oil pricesAnalyst Downgrade & Verified Chart Pattern Trade Signals - baoquankhu1.vn

Feb 14, 2026

Feb 13, 2026

Earnings call transcript: Veru Inc. Q1 2026 sees stock rise amid strategic shifts - Investing.com Nigeria

Feb 13, 2026

Feb 12, 2026

Veru outlines new Phase IIb obesity trial and targets interim analysis in Q1 2027 while increasing cash reserves - MSN

Feb 12, 2026

Feb 12, 2026

Veru Inc. (NASDAQ:VERU) Q1 2026 Earnings Call Transcript - Insider Monkey

Feb 12, 2026

Feb 11, 2026

Veru Q1 2026 Earnings Call Transcript - MarketBeat

Feb 11, 2026

Feb 11, 2026

Veru Inc. Charts Risky but Clearer Post-GLP-1 Path - TipRanks

Feb 11, 2026

Feb 11, 2026

Veru Inc (VERU) Q1 2026 Earnings Call Highlights: Strategic Advances Amid Financial Challenges By GuruFocus - Investing.com Canada

Feb 11, 2026

Feb 11, 2026

Veru Inc. (VERU) Advances Clinical Pipeline with Enobosarm and S - GuruFocus

Feb 11, 2026

Feb 11, 2026

Veru Inc (VERU) Q1 2026 Earnings Call Highlights: Strategic Adva - GuruFocus

Feb 11, 2026

Feb 11, 2026

VERU INC. SEC 10-Q Report - TradingView

Feb 11, 2026

Feb 11, 2026

VERU: No revenue, $5.3M net loss, $33M cash, strategic shift to drug development, going concern risk - TradingView

Feb 11, 2026

Feb 11, 2026

Earnings call transcript: Veru Inc. Q1 2026 sees stock rise amid strategic shifts By Investing.com - Investing.com South Africa

Feb 11, 2026

Feb 11, 2026

Veru (VERU) Q1 2026 Earnings Call Transcript - The Globe and Mail

Feb 11, 2026

Feb 11, 2026

VERU: Net loss narrowed, cash reserves rose, and enobosarm advances with FDA support for new trials - TradingView

Feb 11, 2026

Feb 11, 2026

Veru reports Q1 EPS (26c) vs. (61c) last year - TipRanks

Feb 11, 2026

Feb 11, 2026

VERU INC (NASDAQ:VERU) Reports Narrower-Than-Expected Q1 Loss, Highlights Key Clinical Trial Timeline - ChartMill

Feb 11, 2026

Feb 11, 2026

Veru Inc. Reports Fiscal 2026 First Quarter Financial Results and Clinical Program Progress - TradingView

Feb 11, 2026